Mendelspod Podcast
The 21st is the Century of Biology. A radical advancement in the knowledge of basic biology and human disease is transforming our world. We interview the heroes beneath the headlines.
- Update frequency
- every 5 days
- Average duration
- 27 minutes
- Episodes
- 505
- Years Active
- 2014 - 2025
Seattle Startup Takes Precision Oncology to the Next Step: Carla Grandori, CEO, SEngine
Carla Grandori was for thirty years a cancer researcher most recently at the Fred Hutch in Seattle. She had her personal reasons for working on cancer, she tells us in today’s show. Now, she’s the …
00:23:54 |
Thu 16 Nov 2017
Immuno Oncology 2017: Looking Back, Looking Forward with Rachel Laing and Olivier Lesueur
Immuno oncology is now the dominant topic at Mendelspod. From shows with CEOs presenting new panels of predictive biomarker tests, to the firsts at the FDA with the CAR-T approvals as well as the fir…
00:28:05 |
Tue 14 Nov 2017
Huh? 30 Million Americans Have a Rare Disease? Howard Jacob on the State of Clinical Sequencing
Here’s a title for you. Chief Genomics Officer. Today’s guest is also the VP of Genomic Medicine and a faculty investigator at the HudsonAlpha Institute for Biotechnology.
This is a public episode.…
This is a public episode.…
00:26:15 |
Thu 09 Nov 2017
With their Own Manufacturing Facility, Seattle Children’s Goes Big into CAR-T, Rare Disease
The past few months have seen the first approvals at the FDA for CAR-T cancer therapies. But trials have been going on for years. And not just by big pharma.
Today’s guest, Dr. Michael Jensen, is a …
Today’s guest, Dr. Michael Jensen, is a …
00:26:58 |
Tue 07 Nov 2017
With Immuno Oncology Comes a New Focus on Rare Cells
Modena, Italy is the town where one of the world's rarest cars were first developed and built: the Ferrari sports car. It’s also home to one of the world’s oldest universities where today’s guest …
00:24:53 |
Wed 01 Nov 2017
We've Become Too Single Variant Centric, Says Deanna Church on Genome Analysis
From 1999 to 2013, Deanna Church was a staff scientist at the NCBI where, for a time, she headed the Genome Reference Consortium. This was the effort to continually update, improve and maintain the …
00:22:17 |
Thu 12 Oct 2017
Clinicians Show High Demand for Single Cell Sequencing, Says Bobby Sebra of Mt. Sinai
If today's guest were a super hero, he'd be High Resolution Sequencing Man.
Bobby Sebra is the Director of Technology Development at the Icahn Institute of Genomics and Multiscale Biology at Mt Sinai …
Bobby Sebra is the Director of Technology Development at the Icahn Institute of Genomics and Multiscale Biology at Mt Sinai …
00:25:27 |
Thu 05 Oct 2017
September 2017 with Nathan and Laura: Venter Blunder, RNAi Returns, and Monthly Science Moments
To honor Laura's pentametric thirst,
We write the summary today in verse.
Was it a quake that had no epicenter,
That silly paper out by J. Craig Venter?
And after years of silencing the market
Has RNAi …
We write the summary today in verse.
Was it a quake that had no epicenter,
That silly paper out by J. Craig Venter?
And after years of silencing the market
Has RNAi …
00:25:41 |
Mon 02 Oct 2017
Charting the Dark Matter of Cancer Genomes with Jim Broach
We’ve heard a lot this year about the search for new structural variants and the hope that scientists will find new causal linkages for diseases such as cancer. But will the genome still yield drama…
00:24:29 |
Tue 26 Sep 2017
Why Childhood Cancers Need Their Own Gene Panel: Tim Triche
When we first talked with Tim Triche of LA Children's Hospital, we found out he was a bit of an outlier among cancer researchers. He was an advocate for poking around in the non-coding RNA.
Today we …
Today we …
00:24:49 |
Thu 21 Sep 2017
Exploring the Exome and the Future of Genomics with Jay Shendure
Back in 2009, University of Washington professor, Jay Shendure, wrote a definitive paper offering up a roadmap for exome sequencing. Since then, the cost of sequencing has come down so far that many …
00:24:44 |
Wed 13 Sep 2017
August 2017 Review with Nathan and Laura: CAR-T Cashes In, Embryos Edited in US, and the Invitae Incident
Back from summer vacation, Nathan and Laura are smoking hot as they look back over some exciting headlines.
The summer boiled over with plenty to talk about, but it was just this week that delivered m…
The summer boiled over with plenty to talk about, but it was just this week that delivered m…
00:20:29 |
Fri 01 Sep 2017
The First In-Human Gene Editing Trial in the U.S. - And It’s Not with CRISPR
The challenge for the first ever in-human gene editing trial, according to today’s guest, is with the delivery to the body.
“At the moment, the easiest place to deliver your gene or genome editing is …
“At the moment, the easiest place to deliver your gene or genome editing is …
00:26:15 |
Tue 08 Aug 2017
Thermo, Pfizer, and Novartis Pull Off a First for NGS in Lung Cancer
Today we get to bring you a feel good story, one of the major achievements so far in precision oncology. Three large companies—Thermo Fisher, Pfizer, and Novartis—put aside their differences to come…
00:25:24 |
Thu 03 Aug 2017
Making Genetic Testing Mainstream Medicine with Sean George, Invitae
Invitae appointed their co-founder Sean George as CEO earlier this year. He joins us to share his bold vision for the field of genetic testing.
This is a public episode. If you'd like to discuss thi…
This is a public episode. If you'd like to discuss thi…
00:27:01 |
Tue 01 Aug 2017
Need Better Standards for Your Clinical Assays? NIST Can Help
The life science tools space is flourishing. Biomedical research output is at an all time high. Today’s guest says there are over 40,000 papers published each year on cancer biomarkers.
But very few…
But very few…
00:23:46 |
Thu 27 Jul 2017
Turning on Your DNA with Justin Kao, Helix
They’re getting a lot of buzz this week. We’re pleased to have Justin Kao, a co-founder of Helix on the program today for the first time.
This is a public episode. If you'd like to discuss this with…
This is a public episode. If you'd like to discuss this with…
00:33:22 |
Tue 25 Jul 2017
Will This New Nano Technology Be the Microarray of Genomic Structural Variation? Barrett Bready, Nabsys
Barrett Bready is back on the program. He’s the CEO of Nabsys, a company with some new technology for genome mapping.
Originally Nabsys had been working to develop nanopore sequencing, but after a re…
Originally Nabsys had been working to develop nanopore sequencing, but after a re…
00:20:35 |
Thu 20 Jul 2017
George Church on What Comes After CRISPR
George Church joins us today. He’s the Robert Winthrop Professor of . . . . well, he’s George Church. And he confirms that, yes, a movie called “Woolly" is being made about his lab. In the next br…
00:31:41 |
Thu 13 Jul 2017
Is CRISPR Controversy Science or Spin? June 2017 Review with Nathan and Laura
It’s the end of the month--and the half year mark--so we open up today's monthly discussion with Nathan and Laura to include some of the headlines we’ve missed this year.
Last month a paper was publis…
Last month a paper was publis…
00:23:56 |
Fri 30 Jun 2017
Disclaimer: The podcast and artwork embedded on this page are the property of Theral Timpson. This content is not affiliated with or endorsed by eachpod.com.